Publication | Open Access
IDO expands human CD4<sup>+</sup>CD25<sup>high</sup> regulatory T cells by promoting maturation of LPS‐treated dendritic cells
139
Citations
37
References
2007
Year
Lymphocyte DevelopmentAdaptive Immune SystemT-regulatory CellImmune RegulationImmunologyLps‐treated Dendritic CellsCd4 T Cell ResponsesImmune SystemOxidative StressInflammationCell SignalingRegulatory T Cell BiologyMolecular SignalingAutoimmune DiseaseDc MaturationLps-induced MaturationAutoimmunityT Cell ImmunityCell BiologyReductive StressCytokineImmune Cell DevelopmentIdo InhibitionDendritic Cell BiologyCellular Immune ResponseMedicine
We have previously shown that human monocyte-derived dendritic cells (DC) express indoleamine 2,3-dioxygenase (IDO), as well as several other enzymes of the kynurenine pathway at the mRNA level upon maturation. The tolerogenic mechanisms of this pathway remain unclear. Here we show that LPS-treated DC metabolize tryptophan as far as quinolinate. We found that IDO contributes to LPS and TNF-alpha + poly(I:C)-induced DC maturation since IDO inhibition using two different inhibitors impairs DC maturation. IDO knock-down using short-hairpin RNA also led to diminished LPS-induced maturation. In line with these results, the tryptophan-derived catabolites 3-hydroxyanthranilic acid and 3-hydroxykynurenine increased maturation of LPS-treated DC. Concerning the molecular mechanisms of this effect, IDO acts as an intermediate pathway in LPS-induced production of reactive oxygen species and NF-kappaB activation, two processes that lead to DC maturation. Finally, we show that mature DC expand CD4(+)CD25(high) regulatory T cells in an IDO-dependent manner. In conclusion, we show that IDO constitutes an intermediate pathway in DC maturation leading to expansion of CD4(+)CD25(high) regulatory T cells.
| Year | Citations | |
|---|---|---|
Page 1
Page 1